ciltacabtagene autoleucel
janssen
['cilta-cel', 'cartitude-2', 'janssen']
 2022 updates: &amp; presented the findings of the cartitude-2 study at the #asco. the multicohort phase ii study evaluates the safety &amp; efficacy of cilta-cel in different myeloma settings, including early lines. learn more: 
#DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the healthcare industry